Ricardo García‐Sánchez

444 total citations
14 papers, 331 citations indexed

About

Ricardo García‐Sánchez is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ricardo García‐Sánchez has authored 14 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Ricardo García‐Sánchez's work include Diabetes Treatment and Management (11 papers), Diabetes Management and Research (9 papers) and Metabolism, Diabetes, and Cancer (5 papers). Ricardo García‐Sánchez is often cited by papers focused on Diabetes Treatment and Management (11 papers), Diabetes Management and Research (9 papers) and Metabolism, Diabetes, and Cancer (5 papers). Ricardo García‐Sánchez collaborates with scholars based in United States, Sweden and Belgium. Ricardo García‐Sánchez's co-authors include Eva Johnsson, Julio Rosenstock, Nalina Dronamraju, Stephan Jacob, Chantal Mathieu, Henrik Toft Sørensen, Pål Hasvold, Reimar W. Thomsen, Lars Pedersen and Kenneth Egstrup and has published in prestigious journals such as Diabetes Obesity and Metabolism, Journal of the American Heart Association and Patient Preference and Adherence.

In The Last Decade

Ricardo García‐Sánchez

14 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ricardo García‐Sánchez United States 10 242 89 68 68 54 14 331
Ramin Rezaeianzadeh Canada 6 196 0.8× 63 0.7× 72 1.1× 54 0.8× 55 1.0× 14 356
Frederick Berro Rivera United States 9 111 0.5× 43 0.5× 67 1.0× 27 0.4× 36 0.7× 38 286
Amanda Fernandes United States 9 179 0.7× 84 0.9× 63 0.9× 31 0.5× 53 1.0× 26 403
Krishmita Siwakoti United States 5 212 0.9× 83 0.9× 105 1.5× 24 0.4× 97 1.8× 13 318
Hairong Zhou China 11 139 0.6× 53 0.6× 46 0.7× 32 0.5× 32 0.6× 35 333
Ole Molskov Bech Denmark 10 247 1.0× 82 0.9× 57 0.8× 29 0.4× 19 0.4× 16 402
Gilson Fernandes United States 8 159 0.7× 80 0.9× 57 0.8× 41 0.6× 45 0.8× 30 447
Susanne Jung Germany 11 183 0.8× 68 0.8× 82 1.2× 19 0.3× 59 1.1× 30 364
Margaret Tiktin United States 6 336 1.4× 86 1.0× 64 0.9× 49 0.7× 11 0.2× 7 480
P McEwan United Kingdom 5 168 0.7× 36 0.4× 38 0.6× 42 0.6× 11 0.2× 18 316

Countries citing papers authored by Ricardo García‐Sánchez

Since Specialization
Citations

This map shows the geographic impact of Ricardo García‐Sánchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricardo García‐Sánchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricardo García‐Sánchez more than expected).

Fields of papers citing papers by Ricardo García‐Sánchez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricardo García‐Sánchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricardo García‐Sánchez. The network helps show where Ricardo García‐Sánchez may publish in the future.

Co-authorship network of co-authors of Ricardo García‐Sánchez

This figure shows the co-authorship network connecting the top 25 collaborators of Ricardo García‐Sánchez. A scholar is included among the top collaborators of Ricardo García‐Sánchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricardo García‐Sánchez. Ricardo García‐Sánchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Johansson, L. E. B., Paul Hockings, Eva Johnsson, et al.. (2020). Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 22(7). 1094–1101. 29 indexed citations
3.
4.
Fenici, Peter, et al.. (2019). <p>Patient perceptions of their glycemic control and its influence on type 2 diabetes outcomes: an international survey of online communities</p>. Patient Preference and Adherence. Volume 13. 295–307. 6 indexed citations
5.
Rosenstock, Julio, Shira Perl, Eva Johnsson, Ricardo García‐Sánchez, & Stephan Jacob. (2019). Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obesity and Metabolism. 21(9). 2152–2162. 19 indexed citations
6.
Mathieu, Chantal, Doina Catrinoiu, Aurelian-Emil Ranetti, et al.. (2018). Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. Diabetes Therapy. 9(4). 1703–1711. 3 indexed citations
7.
Prato, Stefano Del, Julio Rosenstock, Ricardo García‐Sánchez, et al.. (2018). Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: P ost‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin. Diabetes Obesity and Metabolism. 20(6). 1542–1546. 16 indexed citations
8.
Rosenstock, Julio, Chantal Mathieu, Hungta Chen, Ricardo García‐Sánchez, & Gabriela Luporini Saraiva. (2018). Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Archives of Endocrinology and Metabolism. 62(4). 424–430. 14 indexed citations
9.
Thomsen, Reimar W., Sia Kromann Nicolaisen, Pål Hasvold, et al.. (2018). Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes. Journal of the American Heart Association. 7(11). 57 indexed citations
10.
Handelsman, Yehuda, Chantal Mathieu, Stefano Del Prato, et al.. (2018). Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obesity and Metabolism. 21(4). 883–892. 17 indexed citations
11.
Müller‐Wieland, Dirk, Monika Kellerer, Katarzyna Cypryk, et al.. (2018). Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 20(11). 2598–2607. 54 indexed citations
12.
García‐Sánchez, Ricardo, et al.. (2014). Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study. Endocrinología y Nutrición (English Edition). 61(1). 18–26. 46 indexed citations
13.
García‐Sánchez, Ricardo, et al.. (2013). Calidad de vida y satisfacción con el tratamiento de sujetos con diabetes tipo 2: resultados en España del estudio PANORAMA. Endocrinología y Nutrición. 61(1). 18–26. 48 indexed citations
14.
García‐Sánchez, Ricardo. (2008). The patient's perspective of computerised records: a questionnairesurvey in primary care. Journal of Innovation in Health Informatics. 16(2). 93–99. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramin Rezaeianzadeh Breakdown of academic impact, for papers by Frederick Berro Rivera Breakdown of academic impact, for papers by Amanda Fernandes Breakdown of academic impact, for papers by Krishmita Siwakoti Breakdown of academic impact, for papers by Hairong Zhou Breakdown of academic impact, for papers by Ole Molskov Bech Breakdown of academic impact, for papers by Gilson Fernandes Breakdown of academic impact, for papers by Susanne Jung Breakdown of academic impact, for papers by Margaret Tiktin Breakdown of academic impact, for papers by P McEwan
Rankless by CCL
2026